Gilead Sciences, Inc (GILD) concluded trading on Thursday at a closing price of $111.11, with 5.59 million shares of worth about $621.4 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 23.20% during that period and on May 29, 2025 the price saw a gain of about 2.46%. Currently the company’s common shares owned by public are about 1.25B shares, out of which, 1.24B shares are available for trading.
Stock saw a price change of 3.15% in past 5 days and over the past one month there was a price change of 6.62%. Year-to-date (YTD), GILD shares are showing a performance of 20.29% which increased to 69.17% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $62.07 but also hit the highest price of $119.96 during that period. The average intraday trading volume for Gilead Sciences, Inc shares is 9.77 million. The stock is currently trading 7.16% above its 20-day simple moving average (SMA20), while that difference is up 5.23% for SMA50 and it goes to 16.76% higher than SMA200.
Gilead Sciences, Inc (NASDAQ: GILD) currently have 1.25B outstanding shares and institutions hold larger chunk of about 86.75% of that.
The stock has a current market capitalization of $138.21B and its 3Y-monthly beta is at 0.30. PE ratio of stock for trailing 12 months is 23.36, while it has posted earnings per share of $4.76 in the same period. Its PEG reads 0.91 and has Quick Ratio of 1.23 while making debt-to-equity ratio of 1.30. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GILD, volatility over the week remained 1.31% while standing at 2.71% over the month.
Analysts are in expectations that Gilead Sciences, Inc (GILD) stock would likely to be making an EPS of 1.95 in the current quarter, while forecast for next quarter EPS is 2.17 and it is 8.47 for next year. For the current quarter EPS, analysts have given the company a lowest target 1.86 which is 2.25 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 2.01 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 73.01% while it is estimated to increase by 6.63% in next year. EPS is likely to grow at an annualized rate of 25.74% for next 5-years, compared to annual growth of -38.13% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on April 22, 2025 offering an Overweight rating for the stock and assigned a target price of $125 to it. Coverage by Oppenheimer stated Gilead Sciences, Inc (GILD) stock as an Outperform in their note to investors on March 04, 2025, suggesting a price target of $132 for the stock. On February 18, 2025, Deutsche Bank Upgrade their recommendations, while on February 13, 2025, DZ Bank Upgrade their ratings for the stock with a price target of $108. Stock get an Overweight rating from Morgan Stanley on January 10, 2025.
